CRISPR technology allows for precise DNA modifications, holding promise for treating genetic disorders and revolutionizing ...

In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene ...

While the Nobel-winning genome-editing technology CRISPR holds great promise, Duke’s Center for Advanced Genomic Technologies ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

The technology’s promise can sound like science fiction—it might help us adapt to a radically different climate, or grow ...

Vertex's diverse pipeline positions it for a growth, despite challenges in launching new drugs like Casgevy and suzetrigine.

All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective ...

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $48.05, representing a +0.47% change from its previous close.

A study reveals that CRISPR gene editing can disable a mutation in melanoma cells that leads to treatment resistance. By targeting the NRAS gene mutation, researchers restored the cells' sensitivity ...

Let's examine what this company is planning for the future, and figure out whether that makes its stock worth buying or not.

In a potential advance for melanoma patients, researchers at ChristianaCare’s Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms of ...

Researchers obtain detailed picture of the specific mechanisms by which each individual mutation studied impacts drug response.